Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Array BioPharma
Array BioPharma
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Array BioPharma closes cancer drug deal with Pierre Fabre
Array may receive up to US$425m in agreement to develop novel oncology products
Manufacturing
Accuratus expands capabilities with acquisition of CMC operations of Array Biopharma
The Array CMC operation will be known as Avista Pharma Solutions and housed in a state-of-the-art, laboratory facility in Longmont, Colorado
Regulatory
Anticancer agent – binimetinib
The new generation of genetically targeted anticancer agents is being developed for melanoma patients with specific mutations
Pharmaceutical
Array BioPharma appoints Victor Sandor as Chief Medical Officer
Clinical oncology expert joins as the company advances its late-stage clinical programmes
Pharmaceutical
Andrew Robbins joins Array BioPharma
Takes newly created role of senior vice president of commercial operations
Pharmaceutical
Array BioPharma appoints new ceo
Ron Squarer joins the US biopharmaceutical firm
Pharmaceutical
Array BioPharma names vp of Regulatory Affairs and Quality Assurance
Howard Holden brings 25 years’ experience to the role
Subscribe now